Chapter 7 · Module 11

Hypertension with Comorbid Cardiovascular Disease

Compelling indications, mechanism-driven agent selection, and integrated targets across comorbidities

HFrEF — Four-Pillar Guideline-Directed Medical Therapy

1 Angiotensin Pathway Inhibition

Sacubitril-valsartan (preferred): PARADIGM-HF — 20% reduction in cardiovascular death and HF hospitalization vs enalapril

ACEi or ARB when sacubitril-valsartan not tolerated

WARNING: Never combine sacubitril-valsartan + ACEi — angioedema risk; 36-hour washout required

2 Beta-Blocker (3 Proven Agents Only)

Carvedilol: COPERNICUS — 35% mortality reduction in severe HFrEF

Metoprolol succinate: MERIT-HF — 34% mortality reduction

Bisoprolol: CIBIS-II — 34% mortality reduction

Start lowest dose when stable; never initiate in acute decompensation

3 Mineralocorticoid Receptor Antagonist

Spironolactone: RALES — 30% mortality reduction (severe HFrEF)

Eplerenone: EMPHASIS-HF — 37% reduction in cardiovascular mortality and HF hospitalization (mild HFrEF)

Contraindicated: K+ above 5.0; creatinine above 2.5 (men) or 2.0 (women); eGFR below 30

4 SGLT2 Inhibitor

Dapagliflozin: DAPA-HF — 26% reduction in composite of cardiovascular death, HF hospitalization, or urgent HF visit regardless of diabetes status

Empagliflozin: EMPEROR-Reduced — Class I GDMT

Additional antihypertensive effect: 3–5 mm Hg systolic reduction

The Critical CCB Distinction in Heart Failure

Non-DHP CCBs (verapamil, diltiazem): ABSOLUTELY CONTRAINDICATED in HFrEF — negative inotropy worsens systolic function and outcomes. Amlodipine (DHP CCB): SAFE in HFrEF — PRAISE trials confirmed no worsening of HF outcomes; amlodipine is the ONLY CCB that can safely be added to HFrEF GDMT for additional BP control.

Compelling Indications — Preferred Agents by Cardiovascular Comorbidity

Agent Selection Matters as Much as the Blood Pressure Target

Mechanism-Driven Drug Selection Across Comorbidities

Comorbidity	Priority Drug Classes	Avoid / Caution
HFrEF	Sacubitril-valsartan or ACEi or ARB + beta-blocker (carvedilol, metoprolol succinate, bisoprolol) + MRA + SGLT2 inhibitor; amlodipine safe for additional BP control; target below 130/80	Non-DHP CCBs — absolutely contraindicated
HFpEF	RAAS inhibitors for BP and LVH regression; SGLT2 inhibitors (Class I or IIa — EMPEROR-Preserved, DELIVER); finerenone (FINEARTS-HF 2024); diuretics for symptoms; target below 130/80	No single class proven to reduce mortality — avoid over-diuresis
Post-MI (EF at or below 40%)	ACEi or ARB (mandatory); beta-blocker; eplerenone (EPHESUS) if EF at or below 40% + HF symptoms or diabetes; target below 130/80; avoid diastolic below 65–70	Non-DHP CCBs and immediate-release nifedipine contraindicated if EF reduced
Stable CAD	Beta-blocker (anti-ischemic + antihypertensive); amlodipine (CAMELOT evidence); ACEi or ARB for secondary prevention (HOPE, EUROPA); target below 130/80; avoid diastolic below 65–70 (J-curve)	Non-DHP CCB + beta-blocker combination (AV block); short-acting DHP CCBs (reflex tachycardia)
Atrial fibrillation	Beta-blocker (rate control + antihypertensive — carvedilol if concurrent HFrEF); non-DHP CCB if no HFrEF (diltiazem preferred); RAAS inhibitor for upstream AF prevention (LIFE trial — losartan vs atenolol); SBP below 130 on anticoagulation	Non-DHP CCB absolutely contraindicated in HFrEF; never combine non-DHP CCB + beta-blocker
Aortic dissection (acute)	Beta-blocker FIRST (esmolol or labetalol IV; target heart rate below 60); add vasodilator only after rate controlled; target systolic 100–120; chronic: SBP below 120–130, beta-blocker + ACEi or ARB; Marfan: add losartan (TGF-beta inhibition)	Vasodilator without prior beta-blocker — reflex tachycardia increases dP/dt and propagates dissection
Peripheral arterial disease	ACEi or ARB (HOPE trial evidence in PAD populations); cardioselective beta-blockers acceptable with cardiac indication; amlodipine (may modestly benefit claudication); target below 130/80; use higher-arm BP for monitoring	Non-selective beta-blockers may worsen claudication

Post-MI Regimen & Atrial Fibrillation Rate Control

Prevention of Remodeling and Mortality Reduction

Post-Myocardial Infarction Pharmacotherapy

ACEi or ARB (mandatory if EF at or below 40% or anterior MI): prevents infarct expansion, ventricular remodeling, and progression to HF; GISSI-3, ISIS-4, SAVE, AIRE — mortality benefit confirmed; VALIANT — valsartan non-inferior to captopril
Beta-blocker: reduces ventricular arrhythmias, sudden death, and reinfarction; carvedilol, metoprolol succinate, or bisoprolol when EF reduced
Eplerenone (EPHESUS — START WITHIN 3–14 DAYS): EF at or below 40% + HF symptoms or diabetes + already on ACEi and beta-blocker → 15% reduction in all-cause mortality; 13% reduction in cardiovascular mortality and morbidity
Target BP: below 130/80 mm Hg; avoid diastolic below 65–70 mm Hg (J-curve — coronary perfusion is diastole-dependent)

Rate Control Agent Selection and Upstream Prevention

Atrial Fibrillation & Hypertension

Beta-blocker (rate control + antihypertensive): first-line in most patients; carvedilol serves dual role as rate control agent and GDMT when HFrEF coexists
Non-DHP CCB (diltiazem or verapamil): effective rate control + antihypertensive; absolutely contraindicated in HFrEF; NEVER combine with beta-blocker (complete heart block); diltiazem preferred (fewer drug interactions, less constipation than verapamil)
RAAS inhibitors for upstream AF prevention: block angiotensin II-mediated atrial fibrosis; reduce left atrial size and electrical remodeling; LIFE trial — losartan significantly reduced new-onset AF vs atenolol in hypertensive LVH
Anticoagulation by CHA₂DS₂-VASc score; hypertension adds 1 point; target SBP below 130 mm Hg on anticoagulation to reduce intracranial hemorrhage risk